Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Enliven Therapeutics, Inc.

NASDAQ: ELVN · Life Sciences · 8 alerts · CIK 1672619

Share price
$47.62Close, Nov 16
Market cap
$3.5B
Shares outstanding
73.6MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Enliven Therapeutics, Inc. filings on SEC EDGAR ↗

4:18 PM ET 10-Q
Financial Results

Enliven Therapeutics Q3 2026 Results: Net Loss of $27.7M, Loss Widens

Enliven Therapeutics reported a significant increase in liquidity, with cash, cash equivalents, and marketable securities totaling approximately $884.4 million as of September 30, 2026, compared to $462.6 million at year-end 2025. The company is advancing its clinical pipeline, specifically relcobatinib (ELVN-001), and preparing for the ENABLE-2 Phase 3 pivotal trial.

Key figure
Net loss $27.7M
4:15 PM ET 8-K
Financial Results

Enliven Therapeutics Financial Results

Enliven Therapeutics reported third quarter 2026 financial results and announced alignment with the FDA on the final design of its ENABLE-2 pivotal Phase 3 trial for relcobatinib. The company ended the quarter with $884.4 million in cash and marketable securities, providing a projected cash runway into 2030.

“This quarter marked an important milestone for Enliven as we reached alignment with the FDA on the final design of ENABLE-2, providing a clear path to initiate our first pivotal trial.”

Rick Fair, Chief Executive Officer of Enliven

“As we approach year-end, we remain confident in relcobatinib's potential to become a best-in-class therapy for patients with CML and are focused on executing our Phase 3 development program.”

Rick Fair, Chief Executive Officer of Enliven
5:54 PM ET Form 4
Insider Selling

Enliven Therapeutics CFO Benjamin Hohl Sells $232K of Stock

Benjamin Hohl, CFO, sold 6,018 shares of Enliven Therapeutics, Inc. at $38.48 a share, worth $232K in total on Oct 19, 2026. Shares held after the trade: 38,000 (-13.7%).

Value
$232K
Shares
6,018
Price
$38.48
Role
CFO
Holding change
-13.7%
Trade date
Oct 19, 2026
5:52 PM ET Form 4
Insider Selling

Enliven Therapeutics CMO Helen Louise Collins Sells $192K of Stock

Helen Louise Collins, CMO, sold 5,000 shares of Enliven Therapeutics, Inc. at $38.47 a share, worth $192K in total on Oct 19, 2026. Shares held after the trade: 25,000 (-16.7%).

Value
$192K
Shares
5,000
Price
$38.47
Role
CMO
Holding change
-16.7%
Trade date
Oct 19, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.